IMTX – Immatics N.V
IMTX
$6.69Name : Immatics N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,018,664,704.00
EPSttm : -1.95
Immatics N.V.
$6.69
IMTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.87
Margin Of Safety %
Put/Call OI Ratio
2.1
EPS Next Q Diff
EPS Last/This Y
-0.24
EPS This/Next Y
0.03
Price
6.7
Target Price
16.55
Analyst Recom
1
Performance Q
-30.24
Upside
-482.8%
Beta
1.37
Ticker: IMTX
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | IMTX | 6.8 | 0.14 | 0.00 | 1721 |
| 2026-10-14 | IMTX | 7.01 | 0.14 | 0.07 | 1722 |
| 2026-10-15 | IMTX | 7.14 | 0.14 | 0.07 | 1722 |
| 2026-10-16 | IMTX | 6.71 | 0.14 | 100.00 | 1736 |
| 2026-10-19 | IMTX | 7.06 | 0.55 | 0.00 | 332 |
| 2026-10-20 | IMTX | 7.51 | 0.55 | 0.00 | 332 |
| 2026-10-21 | IMTX | 7.69 | 0.54 | 0.00 | 337 |
| 2026-10-22 | IMTX | 7.54 | 0.54 | 0.00 | 337 |
| 2026-10-23 | IMTX | 7.32 | 0.45 | 0.00 | 379 |
| 2026-10-26 | IMTX | 7.16 | 0.45 | 0.00 | 379 |
| 2026-10-27 | IMTX | 7.26 | 0.40 | 0.00 | 410 |
| 2026-10-28 | IMTX | 7.34 | 0.40 | 0.00 | 412 |
| 2026-10-29 | IMTX | 7.32 | 0.18 | 0.00 | 773 |
| 2026-10-30 | IMTX | 7.2 | 0.18 | 5.00 | 775 |
| 2026-11-02 | IMTX | 7.04 | 0.52 | 0.00 | 935 |
| 2026-11-03 | IMTX | 7.07 | 0.58 | 0.00 | 865 |
| 2026-11-04 | IMTX | 6.9 | 0.58 | 0.00 | 865 |
| 2026-11-05 | IMTX | 6.17 | 0.83 | 45.64 | 699 |
| 2026-11-06 | IMTX | 6.36 | 0.83 | 45.73 | 699 |
| 2026-11-09 | IMTX | 6.42 | 0.83 | 45.73 | 699 |
| 2026-11-10 | IMTX | 6.42 | 0.83 | 45.73 | 699 |
| 2026-11-11 | IMTX | 6.7 | 2.10 | 0.00 | 1211 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | IMTX | 6.82 | -3.2 | - | -2.07 |
| 2026-10-14 | IMTX | 7.02 | -3.2 | - | -2.07 |
| 2026-10-15 | IMTX | 7.14 | -3.2 | - | -2.07 |
| 2026-10-16 | IMTX | 6.71 | -2.7 | - | -2.06 |
| 2026-10-19 | IMTX | 7.06 | -2.7 | - | -2.06 |
| 2026-10-20 | IMTX | 7.06 | -2.7 | - | -2.06 |
| 2026-10-21 | IMTX | 7.50 | -2.7 | - | -2.06 |
| 2026-10-22 | IMTX | 7.53 | -2.7 | - | -2.06 |
| 2026-10-23 | IMTX | 7.31 | -2.7 | - | -2.06 |
| 2026-10-26 | IMTX | 7.15 | -2.7 | - | -2.06 |
| 2026-10-27 | IMTX | 7.26 | -2.7 | - | -2.06 |
| 2026-10-28 | IMTX | 7.34 | -2.7 | - | -2.06 |
| 2026-10-29 | IMTX | 7.32 | -2.7 | - | -2.06 |
| 2026-10-30 | IMTX | 7.19 | -2.2 | - | -2.05 |
| 2026-11-02 | IMTX | 7.04 | -2.2 | - | -2.05 |
| 2026-11-03 | IMTX | 7.08 | -2.2 | - | -2.05 |
| 2026-11-04 | IMTX | 6.89 | -2.2 | - | -2.05 |
| 2026-11-05 | IMTX | 6.16 | -2.2 | - | -2.05 |
| 2026-11-06 | IMTX | 6.35 | -1.7 | - | -2.04 |
| 2026-11-09 | IMTX | 6.43 | -1.7 | - | -2.04 |
| 2026-11-10 | IMTX | 6.43 | -1.7 | - | -2.04 |
| 2026-11-11 | IMTX | 6.70 | -1.7 | - | -2.04 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | IMTX | 4.10 | -4.75 | 2.89 |
| 2026-10-14 | IMTX | 4.10 | -4.75 | 2.89 |
| 2026-10-15 | IMTX | 4.10 | -4.75 | 2.89 |
| 2026-10-16 | IMTX | 4.10 | -4.75 | 2.89 |
| 2026-10-19 | IMTX | 4.10 | -4.43 | 2.89 |
| 2026-10-20 | IMTX | 4.10 | -4.43 | 2.89 |
| 2026-10-21 | IMTX | 4.10 | -4.43 | 2.89 |
| 2026-10-22 | IMTX | 4.10 | -4.43 | 2.89 |
| 2026-10-23 | IMTX | 4.10 | -4.43 | 2.89 |
| 2026-10-26 | IMTX | 4.10 | -4.33 | 2.89 |
| 2026-10-27 | IMTX | 4.10 | -4.33 | 2.93 |
| 2026-10-28 | IMTX | 4.10 | -4.33 | 2.93 |
| 2026-10-29 | IMTX | 4.10 | -4.33 | 2.93 |
| 2026-10-30 | IMTX | 4.10 | -4.33 | 2.93 |
| 2026-11-02 | IMTX | 4.10 | -4.34 | 2.93 |
| 2026-11-03 | IMTX | 4.10 | -4.34 | 2.93 |
| 2026-11-05 | IMTX | 4.10 | -4.34 | 2.93 |
| 2026-11-06 | IMTX | 4.10 | -4.34 | 2.93 |
| 2026-11-09 | IMTX | 4.10 | -4.43 | 2.93 |
| 2026-11-10 | IMTX | 4.10 | -4.43 | 2.93 |
| 2026-11-11 | IMTX | 4.10 | -4.43 | 2.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.5
Avg. EPS Est. Next Quarter
-0.48
Insider Transactions
4.1
Institutional Transactions
-4.43
Beta
1.37
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
13
Fair Value
Quality Score
32
Growth Score
25
Sentiment Score
4
Actual DrawDown %
52.1
Max Drawdown 5-Year %
-74.1
Target Price
16.55
P/E
Forward P/E
PEG
P/S
19.82
P/B
2.05
P/Free Cash Flow
EPS
-1.97
Average EPS Est. Cur. Y
-2.04
EPS Next Y. (Est.)
-2
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-533.26
Relative Volume
1.1
Return on Equity vs Sector %
-78.6
Return on Equity vs Industry %
-59
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
◆
IMTX
Healthcare
$6.69
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
17/25
Volume
4/15
Valuation
12/20
TP/AR
2/10
Options
4/10
RSI
40.5
Range 1M
34.7%
Sup Dist
8.1%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
0/25
Growth
8/30
Estimates
0/20
Inst/Vol
2/15
Options
2/10
EPS Yr
-16.3%
EPS NY
0%
52W%
10.2%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+147.4% upside
Quality
2/30
Valuation
15/30
Growth
3/25
Stability
7/10
LT Trend
1/5
Upside
+147.4%
Quality
32
Click a card to see score breakdown
Full Analysis →
IMTX — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 589
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX
Latest News
—
Caricamento notizie per IMTX…
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading